×
S&P 500   4,131.20 (+1.81%)
DOW   32,991.92 (+1.09%)
QQQ   306.91 (+2.53%)
AAPL   148.49 (+3.28%)
MSFT   270.58 (+1.76%)
FB   193.92 (+1.20%)
GOOGL   2,229.79 (+3.43%)
AMZN   2,266.05 (+2.00%)
TSLA   752.23 (+6.29%)
NVDA   185.89 (+4.13%)
BABA   93.28 (-1.27%)
NIO   16.42 (+2.43%)
AMD   101.46 (+2.74%)
CGC   4.88 (-12.07%)
MU   73.02 (+3.43%)
T   21.22 (-0.47%)
GE   77.88 (+1.13%)
F   13.56 (+3.35%)
DIS   108.40 (+2.64%)
AMC   13.95 (+14.06%)
PFE   53.56 (-0.80%)
PYPL   84.95 (+5.63%)
NFLX   194.27 (+1.50%)
S&P 500   4,131.20 (+1.81%)
DOW   32,991.92 (+1.09%)
QQQ   306.91 (+2.53%)
AAPL   148.49 (+3.28%)
MSFT   270.58 (+1.76%)
FB   193.92 (+1.20%)
GOOGL   2,229.79 (+3.43%)
AMZN   2,266.05 (+2.00%)
TSLA   752.23 (+6.29%)
NVDA   185.89 (+4.13%)
BABA   93.28 (-1.27%)
NIO   16.42 (+2.43%)
AMD   101.46 (+2.74%)
CGC   4.88 (-12.07%)
MU   73.02 (+3.43%)
T   21.22 (-0.47%)
GE   77.88 (+1.13%)
F   13.56 (+3.35%)
DIS   108.40 (+2.64%)
AMC   13.95 (+14.06%)
PFE   53.56 (-0.80%)
PYPL   84.95 (+5.63%)
NFLX   194.27 (+1.50%)
S&P 500   4,131.20 (+1.81%)
DOW   32,991.92 (+1.09%)
QQQ   306.91 (+2.53%)
AAPL   148.49 (+3.28%)
MSFT   270.58 (+1.76%)
FB   193.92 (+1.20%)
GOOGL   2,229.79 (+3.43%)
AMZN   2,266.05 (+2.00%)
TSLA   752.23 (+6.29%)
NVDA   185.89 (+4.13%)
BABA   93.28 (-1.27%)
NIO   16.42 (+2.43%)
AMD   101.46 (+2.74%)
CGC   4.88 (-12.07%)
MU   73.02 (+3.43%)
T   21.22 (-0.47%)
GE   77.88 (+1.13%)
F   13.56 (+3.35%)
DIS   108.40 (+2.64%)
AMC   13.95 (+14.06%)
PFE   53.56 (-0.80%)
PYPL   84.95 (+5.63%)
NFLX   194.27 (+1.50%)
S&P 500   4,131.20 (+1.81%)
DOW   32,991.92 (+1.09%)
QQQ   306.91 (+2.53%)
AAPL   148.49 (+3.28%)
MSFT   270.58 (+1.76%)
FB   193.92 (+1.20%)
GOOGL   2,229.79 (+3.43%)
AMZN   2,266.05 (+2.00%)
TSLA   752.23 (+6.29%)
NVDA   185.89 (+4.13%)
BABA   93.28 (-1.27%)
NIO   16.42 (+2.43%)
AMD   101.46 (+2.74%)
CGC   4.88 (-12.07%)
MU   73.02 (+3.43%)
T   21.22 (-0.47%)
GE   77.88 (+1.13%)
F   13.56 (+3.35%)
DIS   108.40 (+2.64%)
AMC   13.95 (+14.06%)
PFE   53.56 (-0.80%)
PYPL   84.95 (+5.63%)
NFLX   194.27 (+1.50%)
LON:AKR

Akers Biosciences (AKR) Share Forecast, Price & News

GBX 57.50
0.00 (0.00%)
(As of 03/28/2019)
Add
Compare
Today's Range
57.50
57.50
50-Day Range
57.50
57.50
52-Week Range
23.50
491.60
Volume
262 shs
Average Volume
818 shs
Market Capitalization
£21.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive AKR News and Ratings via Email

Sign-up to receive the latest news and ratings for Akers Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Akers Biosciences logo

About Akers Biosciences

Akers Biosciences, Inc., together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States, the People's Republic of China, and internationally. The company's marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness. Its marketed products also include PIFA Heparin/PF4 and PIFA PLUSS PF4 rapid tests for Heparin/PF4 antibodies to detect an allergy to the used blood thinner, Heparin; seraSTAT, a rapid blood cell separator; Tri-Cholesterol 'Check', a rapid test for total and high density lipoprotein cholesterol and estimates low density lipo protein; and BreathScan OxiCHek, a breath test for oxidative stress using the Lync reader and digital app. The company's pipeline products comprise Breath Diabetic Ketoacidosis, a disposable breath ketone device for diabetic monitoring; Breath PulmoHealth 'Check', a suite of breath tests for biomarkers indicating asthma, chronic obstructive pulmonary disease, and lung cancer; PIFA PLUSS Chlamydia, a rapid test for sexually transmitted diseases; and BreathScan KetoChek, a breath test for ketosis using the Lync reader and digital app. Akers Biosciences, Inc. was founded in 1989 and is headquartered in Thorofare, New Jersey.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Medical Instruments & Supplies
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
32
Year Founded
N/A

Sales & Book Value

Annual Sales
£2.32 million
Cash Flow
GBX 63.76 per share
Book Value
GBX 65.50 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
£21.64 million
Optionable
Optionable

MarketRank

Overall MarketRank

0.90 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -













Akers Biosciences (LON:AKR) Frequently Asked Questions

Who are Akers Biosciences' key executives?
Akers Biosciences' management team includes the following people:
  • Mr. Gary M. Rauch, VP of Fin. & Treasurer (Age 63)
  • Mr. Howard R. Yeaton Jr., CPA, CEO & Interim CFO (Age 64)
  • Mr. Douglas Carrara, Sr. VP of Global Marketing & Commercial Operations
  • Ms. Pamela E. Hibler, VP of Sales & Distribution
What other stocks do shareholders of Akers Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akers Biosciences investors own include SandRidge Permian Trust (PER), Rite Aid (RAD), AT&T (T), BP (BP), Cross Timbers Royalty Trust (CRT), Solbright Group (SBRT), Broadcom (AVGO), Achillion Pharmaceuticals (ACHN), Akamai Technologies (AKAM) and Akorn (AKRX).

What is Akers Biosciences' stock symbol?

Akers Biosciences trades on the London Stock Exchange (LON) under the ticker symbol "AKR."

How do I buy shares of Akers Biosciences?

Shares of AKR and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Akers Biosciences' stock price today?

One share of AKR stock can currently be purchased for approximately GBX 57.50.

How much money does Akers Biosciences make?

Akers Biosciences has a market capitalization of £21.64 million and generates £2.32 million in revenue each year.

How many employees does Akers Biosciences have?

Akers Biosciences employs 32 workers across the globe.

What is Akers Biosciences' official website?

The official website for Akers Biosciences is www.akersbio.com.

How can I contact Akers Biosciences?

Akers Biosciences' mailing address is 201 Grove Rd, WEST DEPTFORD, NJ 08086-2231, United States. The company can be reached via phone at +1-856-8488698.

This page was last updated on 5/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.